GLAND PHARMA LATEST UPDATES

Latest Financial Performance (Q2 FY2025-26) For the quarter ending September 2025, Gland Pharma reported a consolidated revenue of ₹1,486.8 crore, a 6% increase year-on-year. Net profit for the period rose 12.3% to ₹184 crore. While the U.S. and European markets showed growth of 10% and 16% respectively, the domestic Indian market and other Rest-of-the-World (RoW) segments saw contractions. Sequentially, the company faced some pressure, with profit after tax (PAT) declining about 15% compared to the June 2025 quarter. Regulatory & Manufacturing Updates In February 2025, the US FDA concluded a pre-approval inspection (PAI) at the company’s sterile API facility in Visakhapatnam (JNPC). The inspection ended with three Form 483 observations, which the company described as procedural and not related to data integrity. On the manufacturing front, Gland successfully commissioned a new high-speed ampoule line at its Cenexi facility in France, which is expected to boost production capacity by 40–50 million units. Product Pipeline & GLP-1 Expansion Gland continues to pivot toward complex injectables. In Q2 FY26, the company launched seven new molecules in the U.S. market, including Daptomycin-RTU and Sumatriptan. A major strategic focus for 2025 has been the GLP-1 segment (weight loss and diabetes drugs); the company is currently scaling its pen and cartridge production capacity from 40 million to 140 million units to meet global demand for these therapies. Strategic Subsidiary Updates (Cenexi) The turnaround of its European subsidiary, Cenexi, remains a key priority. While Cenexi reported a 21% top-line increase in Q2 FY26, it recorded a marginal EBITDA loss due to planned maintenance shutdowns and infrastructure upgrades. Management has adjusted the timeline for Cenexi to reach full EBITDA profitability to the third quarter of FY2025-26, supported by the new production lines and a current order book of approximately €100 million.